Advertisement

Clinical Trials That Have Informed the Modern Management of Breast Cancer

Published:November 03, 2022DOI:https://doi.org/10.1016/j.soc.2022.07.004

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fisher B.
        • Jeong J.H.
        • Anderson S.
        • et al.
        Twenty-Five-Year Follow-up of a Randomized Trial Comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy Followed by Irradiation.
        N Engl J Med. 2002; 347: 567-575
        • Fentiman I.S.
        Long-term follow-up of the first breast conservation trial: Guy’ wide excision study.
        Breast Edinb Scotl. 2000; 9: 5-8
        • Mathis K.L.
        • Nelson H.
        Randomized Controlled Trials in Surgical Oncology.
        Surg Oncol Clin N Am. 2012; 21: 449-466
        • Keynes G.
        The Radium Treatment of Primary Carcinoma of the Breast ∗Read 25th November 1930.
        Edinb Med J. 1931; 38: T19-T36
        • Veronesi U.
        • Saccozzi R.
        • Del Vecchio M.
        • et al.
        Comparing Radical Mastectomy with Quadrantectomy, Axillary Dissection, and Radiotherapy in Patients with Small Cancers of the Breast.
        N Engl J Med. 1981; 305: 6-11
        • Veronesi U.
        • Cascinelli N.
        • Mariani L.
        • et al.
        Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer.
        N Engl J Med. 2002; 347: 1227-1232
      1. Review of Breast Cancer Clinical Trials Conducted by the National Surgical Adjuvant Breast Project - ClinicalKey.
        (Available at:) (Accessed November 30, 2021)
        • Sarrazin D.
        • Lê M.G.
        • Arriagada R.
        • et al.
        Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer.
        Radiother Oncol J Eur Soc Ther Radiol Oncol. 1989; 14: 177-184
        • Fisher B.
        • Anderson S.
        • Bryant J.
        • et al.
        Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer.
        N Engl J Med. 2002; 347: 1233-1241
        • Fisher B.
        • Anderson S.
        • Redmond C.K.
        • et al.
        Reanalysis and Results after 12 Years of Follow-up in a Randomized Clinical Trial Comparing Total Mastectomy with Lumpectomy with or without Irradiation in the Treatment of Breast Cancer.
        N Engl J Med. 1995; 333: 1456-1461
        • Litière S.
        • Werutsky G.
        • Fentiman I.S.
        • et al.
        Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial.
        Lancet Oncol. 2012; 13: 412-419
        • Jacobson J.A.
        • Danforth D.N.
        • Cowan K.H.
        • et al.
        Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer.
        N Engl J Med. 1995; 332: 907-911
        • Poggi M.M.
        • Danforth D.N.
        • Sciuto L.C.
        • et al.
        Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.
        Cancer. 2003; 98: 697-702
        • Blichert-Toft M.
        • Rose C.
        • Andersen J.A.
        • et al.
        Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group.
        J Natl Cancer Inst Monogr. 1992; 11: 19-25
      2. Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials | NEJM.
        (Available at:) (Accessed December 3, 2021)
        • Liljegren G.
        • Holmberg L.
        • Bergh J.
        • et al.
        10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial.
        J Clin Oncol. 1999; 17: 2326-2333
        • Clark R.M.
        • McCulloch P.B.
        • Levine M.N.
        • et al.
        Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer.
        J Natl Cancer Inst. 1992; 84: 683-689
        • Clark R.M.
        • Whelan T.
        • Levine M.
        • et al.
        Randomized Clinical Trial of Breast Irradiation Following Lumpectomy and Axillary Dissection for Node-Negative Breast Cancer: an Update.
        JNCI J Natl Cancer Inst. 1996; 88: 1659-1664
        • Veronesi U.
        • Marubini E.
        • Mariani L.
        • et al.
        Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial.
        Ann Oncol. 2001; 12: 997-1003
        • Hughes K.S.
        • Schnaper L.A.
        • Berry D.
        • et al.
        Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer.
        N Engl J Med. 2004; 351: 971-977
        • Hughes K.S.
        • Schnaper L.A.
        • Bellon J.R.
        • et al.
        Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343.
        J Clin Oncol. 2013; 31: 2382-2387
        • Kunkler I.H.
        • Williams L.J.
        • Jack W.J.L.
        • et al.
        PRIME II investigators. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
        Lancet Oncol. 2015; 16: 266-273
        • Fisher B.
        • Costantino J.
        • Redmond C.
        • et al.
        Lumpectomy Compared with Lumpectomy and Radiation Therapy for the Treatment of Intraductal Breast Cancer.
        N Engl J Med. 1993; 328: 1581-1586
        • Fisher B.
        • Dignam J.
        • Wolmark N.
        • et al.
        Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.
        Lancet Lond Engl. 1999; 353: 1993-2000
        • Fisher B.
        • Bryant J.
        • Dignam J.J.
        • et al.
        Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
        J Clin Oncol. 2002; 20: 4141-4149
        • Moran M.S.
        • Schnitt S.J.
        • Giuliano A.E.
        • et al.
        SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Surgery with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer.
        Int J Radiat Oncol Biol Phys. 2014; 88: 553-564
      3. Guidelines Detail. NCCN.
        (Available at:) (Accessed January 19, 2022)
        • Houssami N.
        • Macaskill P.
        • Luke Marinovich M.
        • et al.
        The Association of Surgical Margins and Local Recurrence in Women with Early-Stage Invasive Breast Cancer Treated with Breast-Conserving Therapy: A Meta-Analysis.
        Ann Surg Oncol. 2014; 21: 717-730
        • Morrow M.
        • Van Zee K.J.
        • Solin L.J.
        • et al.
        Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Ductal Carcinoma In Situ.
        J Clin Oncol. 2016; 34: 4040-4046
        • Wapnir I.L.
        • Dignam J.J.
        • Fisher B.
        • et al.
        Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.
        J Natl Cancer Inst. 2011; 103: 478-488
        • Houghton J.
        • George W.D.
        • Cuzick J.
        • et al.
        Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.
        Lancet Lond Engl. 2003; 362: 95-102
        • Julien J.P.
        • Bijker N.
        • Fentiman I.S.
        • et al.
        Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
        Lancet Lond Engl. 2000; 355: 528-533
        • Emdin S.O.
        • Granstrand B.
        • Ringberg A.
        • et al.
        SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening.
        Acta Oncol Stockh Swed. 2006; 45: 536-543
        • Krag D.N.
        • Anderson S.J.
        • Julian T.B.
        • et al.
        Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial.
        Lancet Oncol. 2007; 8: 881-888
        • Krag D.N.
        • Anderson S.J.
        • Julian T.B.
        • et al.
        Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
        Lancet Oncol. 2010; 11: 927-933
        • Zavagno G.
        • De Salvo G.L.
        • Scalco G.
        • et al.
        A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial.
        Ann Surg. 2008; 247: 207-213
        • Veronesi U.
        • Paganelli G.
        • Viale G.
        • et al.
        Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study.
        Lancet Oncol. 2006; 7: 983-990
        • Veronesi U.
        • Viale G.
        • Paganelli G.
        • et al.
        Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study.
        Ann Surg. 2010; 251: 595-600
        • Canavese G.
        • Catturich A.
        • Vecchio C.
        • et al.
        Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial.
        Ann Oncol. 2009; 20: 1001-1007
        • Wilke L.G.
        • McCall L.M.
        • Posther K.E.
        • et al.
        Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial.
        Ann Surg Oncol. 2006; 13: 491-500
        • Galimberti V.
        • Cole B.F.
        • Zurrida S.
        • et al.
        Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial.
        Lancet Oncol. 2013; 14: 297-305
        • Giuliano A.E.
        • Hunt K.K.
        • Ballman K.V.
        • et al.
        Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis: A Randomized Clinical Trial.
        JAMA. 2011; 305: 569-575
        • Giuliano A.E.
        • Ballman K.V.
        • McCall L.
        • et al.
        Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
        JAMA. 2017; 318: 918-926
        • Donker M.
        • van Tienhoven G.
        • Straver M.E.
        • et al.
        Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
        Lancet Oncol. 2014; 15: 1303-1310
        • Sávolt Á.
        • Péley G.
        • Polgár C.
        • et al.
        Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
        Eur J Surg Oncol. 2017; 43: 672-679
        • Whelan T.J.
        • Olivotto I.A.
        • Parulekar W.R.
        • et al.
        Regional Nodal Irradiation in Early-Stage Breast Cancer.
        N Engl J Med. 2015; 373: 307-316
        • Katz M.S.
        • McCall L.
        • Ballman K.
        • et al.
        Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations.
        Breast Cancer Res Treat. 2020; 180: 429-436
        • Boughey J.C.
        • Suman V.J.
        • Mittendorf E.A.
        • et al.
        Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
        JAMA. 2013; 310: 1455-1461
        • Caudle A.S.
        • Yang W.T.
        • Krishnamurthy S.
        • et al.
        Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection.
        J Clin Oncol. 2016; 34: 1072-1078
        • Kuehn T.
        • Bauerfeind I.
        • Fehm T.
        • et al.
        Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.
        Lancet Oncol. 2013; 14: 609-618
        • Boileau J.F.
        • Poirier B.
        • Basik M.
        • et al.
        Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study.
        J Clin Oncol. 2015; 33: 258-264
        • Classe J.M.
        • Loaec C.
        • Gimbergues P.
        • et al.
        Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.
        Breast Cancer Res Treat. 2019; 173: 343-352
        • Boughey J.C.
        • Ballman K.V.
        • McCall L.M.
        • et al.
        Tumor Biology and Response to Chemotherapy Impact Breast Cancer-Specific Survival in Node-Positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Long-term Follow-up from ACOSOG Z1071 (Alliance).
        Ann Surg. 2017; 266: 667-676
        • Samiei S.
        • Simons J.M.
        • Engelen S.M.E.
        • et al.
        Axillary Pathologic Complete Response After Neoadjuvant Systemic Therapy by Breast Cancer Subtype in Patients With Initially Clinically Node-Positive Disease: A Systematic Review and Meta-analysis.
        JAMA Surg. 2021; 156: e210891
        • de Boniface J.
        • Frisell J.
        • Andersson Y.
        • et al.
        Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial.
        BMC Cancer. 2017; 17: 379
      4. Alliance for Clinical Trials in Oncology. A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (CT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy. clinicaltrials.gov; 2022.
        (Available at:) (Accessed March 1, 2022)
        • Fisher B.
        • Ravdin R.G.
        • Ausman R.K.
        • et al.
        Surgical adjuvant chemotherapy in cancer of the breast: results of a decade of cooperative investigation.
        Ann Surg. 1968; 168: 337-356
        • Bonadonna G.
        • Valagussa P.
        • Moliterni A.
        • et al.
        Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up.
        N Engl J Med. 1995; 332: 901-906
        • Fisher B.
        • Dignam J.
        • Mamounas E.P.
        • et al.
        Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
        J Clin Oncol. 1996; 14: 1982-1992
        • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
        Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
        Lancet Lond Engl. 2019; 393: 1440-1452
        • Anampa J.
        • Makower D.
        • Sparano J.A.
        Progress in adjuvant chemotherapy for breast cancer: an overview.
        BMC Med. 2015; 13: 195
        • Perez E.A.
        • Romond E.H.
        • Suman V.J.
        • et al.
        Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.
        J Clin Oncol. 2014; 32: 3744-3752
        • Romond E.H.
        • Perez E.A.
        • Bryant J.
        • et al.
        Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer.
        N Engl J Med. 2005; 353: 1673-1684
        • Cameron D.
        • Piccart-Gebhart M.J.
        • Gelber R.D.
        • et al.
        11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
        Lancet Lond Engl. 2017; 389: 1195-1205
        • von Minckwitz G.
        • Procter M.
        • de Azambuja E.
        • et al.
        Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.
        N Engl J Med. 2017; 377: 122-131
        • Hurvitz S.A.
        • Gelmon K.A.
        • Tolaney S.M.
        Optimal Management of Early and Advanced HER2 Breast Cancer.
        Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet. 2017; 37: 76-92
        • Fisher B.
        • Bryant J.
        • Wolmark N.
        • et al.
        Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
        J Clin Oncol. 1998; 16: 2672-2685
        • Rastogi P.
        • Anderson S.J.
        • Bear H.D.
        • et al.
        Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.
        J Clin Oncol. 2008; 26: 778-785
        • Mamounas E.P.
        • Anderson S.J.
        • Dignam J.J.
        • et al.
        Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
        J Clin Oncol. 2012; 30: 3960-3966
        • Gianni L.
        • Pienkowski T.
        • Im Y.H.
        • et al.
        5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
        Lancet Oncol. 2016; 17: 791-800
        • Schneeweiss A.
        • Chia S.
        • Hickish T.
        • et al.
        Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer.
        Eur J Cancer Oxf Engl 1990. 2018; 89: 27-35
        • Leon-Ferre R.A.
        • Hieken T.J.
        • Boughey J.C.
        The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer.
        Ann Surg Oncol. 2021; 28: 2111-2119
        • Schmid P.
        • Cortes J.
        • Pusztai L.
        • et al.
        Pembrolizumab for Early Triple-Negative Breast Cancer.
        N Engl J Med. 2020; 382: 810-821
        • Barnard K.
        • Klimberg V.S.
        An Update on Randomized Clinical Trials in Breast Cancer.
        Surg Oncol Clin N Am. 2017; 26: 587-620
        • Rugo H.S.
        • Olopade O.I.
        • DeMichele A.
        • et al.
        Adaptive Randomization of Veliparib–Carboplatin Treatment in Breast Cancer.
        N Engl J Med. 2016; https://doi.org/10.1056/NEJMoa1513749
        • Masuda N.
        • Lee S.J.
        • Ohtani S.
        • et al.
        Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
        N Engl J Med. 2017; 376: 2147-2159
      5. M.D. Anderson Cancer Center. Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy. clinicaltrials.gov; 2021.
        (Available at:) (Accessed March 2, 2022)
        • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
        Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
        Lancet Lond Engl. 2005; 365: 1687-1717
        • Fisher B.
        • Dignam J.
        • Bryant J.
        • et al.
        Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
        J Natl Cancer Inst. 1996; 88: 1529-1542
        • Fisher B.
        • Dignam J.
        • Emir B.
        • et al.
        Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer.
        JNCI J Natl Cancer Inst. 1997; 89: 1673-1682
        • Mouridsen H.
        • Gershanovich M.
        • Sun Y.
        • et al.
        Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group.
        J Clin Oncol. 2003; 21: 2101-2109
        • Mouridsen H.
        • Gershanovich M.
        • Sun Y.
        • et al.
        Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
        J Clin Oncol. 2001; 19: 2596-2606
        • Goss P.E.
        • Ingle J.N.
        • Martino S.
        • et al.
        Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
        J Natl Cancer Inst. 2005; 97: 1262-1271
        • Burstein H.J.
        • Lacchetti C.
        • Anderson H.
        • et al.
        Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
        J Clin Oncol. 2019; 37: 423-438
        • Burstein H.J.
        • Lacchetti C.
        • Anderson H.
        • et al.
        Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.
        J Clin Oncol. 2016; 34: 1689-1701
        • Ellis M.J.
        • Suman V.J.
        • Hoog J.
        • et al.
        Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
        J Clin Oncol. 2011; 29: 2342-2349
        • Sparano J.A.
        • Gray R.J.
        • Makower D.F.
        • et al.
        Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.
        N Engl J Med. 2018; 379: 111-121
      6. Postmenopausal Women with HR+/HER2– Early Breast Cancer, 1–3 Positive Nodes, and a Low Risk of Recurrence Can Safely Forego Chemotherapy.
        Oncologist. 2021; 26: S11-S12
        • Kalinsky K.
        • Barlow W.E.
        • Gralow J.R.
        • et al.
        21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.
        N Engl J Med. 2021; 385: 2336-2347
        • Cardoso F.
        • van’t Veer L.J.
        • Bogaerts J.
        • et al.
        70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
        N Engl J Med. 2016; 375: 717-729
        • Piccart M.
        • van ’t Veer L.J.
        • Poncet C.
        • et al.
        70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
        Lancet Oncol. 2021; 22: 476-488